LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genetic Tool Monitors and Manipulates Cellular Protein Aggregates

By LabMedica International staff writers
Posted on 30 Oct 2017
Image: The yTRAP can be used to create cellular sensors for protein aggregation. The sensor produces fluorescent signals that depend on the protein aggregation state in the cell. In this experiment, three cell types were tested that produce varying signal strength depending on the aggregation of a prion protein. The brightest green for no prion aggregation (bottom), a slightly dimmer green to show a weak presence of prion aggregation (top right) and an even dimmer green signal for a strong prion presence (top left) (Photo courtesy of Dr. Ahmad S. Khalil).
Image: The yTRAP can be used to create cellular sensors for protein aggregation. The sensor produces fluorescent signals that depend on the protein aggregation state in the cell. In this experiment, three cell types were tested that produce varying signal strength depending on the aggregation of a prion protein. The brightest green for no prion aggregation (bottom), a slightly dimmer green to show a weak presence of prion aggregation (top right) and an even dimmer green signal for a strong prion presence (top left) (Photo courtesy of Dr. Ahmad S. Khalil).
A newly developed genetic tool allows researchers to track the level of protein aggregation in cells, and to a certain extent, manipulate or eliminate the aggregates.

Protein aggregation is a hallmark of many diseases but also underlies a wide range of positive cellular functions. This phenomenon has been difficult to study because of a lack of quantitative and high-throughput cellular tools.

To correct this lack, investigators at the Boston University College of Engineering (MA, USA) developed a synthetic genetic tool to sense and control protein aggregation. This tool - called yTRAP for yeast Transcriptional Reporting of Aggregating Proteins - was composed of two parts: one segment attached to the protein of interest and the other produced a fluorescent signal to measure the amount of aggregation in the cell.

The investigators worked with a yeast model system. They ported in the October 19, 2017, online edition of the journal Cell that by utilizing high-throughput screens, they were able to identify prion-curing mutants and engineer “anti-prion drives” that reversed the non-Mendelian inheritance pattern of prions and eliminated them from yeast populations. They extended ther technology to yeast RNA-binding proteins (RBPs) by tracking their propensity to aggregate, searching for co-occurring aggregates, and uncovering a group of coalescing RBPs through screens enabled by the platform.

This work established a quantitative, high-throughput, and generalized technology to study and control diverse protein aggregation processes in cells.

"Protein aggregates can cause a cell to gain or lose a function," said senior author Dr. Ahmad S. Khalil, assistant professor of biomedical engineering at Boston University College of Engineering. "It could be beneficial or harmful. For example, it could allow a cell to survive stressful conditions or change its metabolic function to digest a different type of sugar. And the discovery of these beneficial functions has often been serendipitous."

Related Links:
Boston University College of Engineering

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more